Insogna KL, Rauch F, Kamenický P, et al. - in adults with X-linked hypophosphatemia (XLH) who have not been treated for at least two years prior to registration, researchers tested the effectiveness of 1.0 mg/kg subcutaneous burosumab (a fully human monoclonal antibody against FGF23) administered every 4 weeks to improve osteomalacia. Fourteen individuals were recruited, 13 finished 48 weeks, and 11 finished paired biopsies. According to this phase 3, single-arm, international trial, burosumab significantly improved osteomalacia in adults with XLH by normalizing phosphate homeostasis, which most likely accounts for improved fracture healing and skeletal complications. Investigators observed that most adverse events were mild to moderate. There were no deaths or incidents involving hyperphosphatemia.